Immuron has reported another quarter of steady sales expansion, underpinned by continued demand for its flagship product Travelan, as the company builds momentum across key international markets.
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 Australian Biotech
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News
